Published in Health Business Week, June 10th, 2005
The phase I portion of this multicenter study will determine the dose, safety, tolerability, and pharmacokinetics of talotrexin in refractory leukemia patients, including both myeloid and lymphoid leukemias. The phase II component will focus on relapsed or refractory ALL patients to determine the efficacy of talotrexin, as measured by complete response rate.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.